Orpyx® launches Orpyx SI Sensory Insoles with Remote Patient Monitoring to Prevent Diabetic Foot Ulcers

News
PatientsProvidersPayers
Orpyx® Medical Technologies Inc. (Orpyx), an innovator in digital health therapeutics, announced the launch of Orpyx SI Sensory Insoles with Remote Patient Monitoring for the prevention of diabetic foot ulcers (DFU) and neuropathy-related ulcers.

CALGARY, Alberta, Dec. 4, 2019 /PRNewswire/ - Orpyx® Medical Technologies Inc. (Orpyx), an innovator in digital health therapeutics, announced the launch of Orpyx SI Sensory Insoles with Remote Patient Monitoring for the prevention of diabetic foot ulcers (DFU) and neuropathy-related ulcers. By monitoring pressure, temperature, and movement, the Orpyx SI Sensory Insole system provides the wearer with real-time audiovisual alerts and allows them to immediately take action to resolve high-pressure areas that may lead to tissue breakdown. Through a cloud-based dashboard, healthcare providers can monitor real-world data and identify trends to proactively make treatment decisions to help keep their patients' feet healthy. To learn more about our product visit here.

It is our mission to eliminate preventable DFUs, stated Dr. Breanne Everett, Orpyx CEO and co-inventor. Current treatments are not enough. One in four people suffering from diabetes will develop a foot ulcer, and after the ulcer has healed, 40% of those will recur within the first year. Once a person develops a DFU, the 5-year mortality rate is almost 50%--higher than leukemia, colon cancer, and breast cancer. In my clinical practice, I saw the physical and emotional toll DFUs had on our patients and their families. If we can prevent DFUs from recurring, we can greatly improve peoples' lives while avoiding costs. It is estimated $176B spent in the US alone on diabetes care, of which $60B is directly related to lower limb care.

In a recently published randomized controlled trial, when compared to standard of care, the Orpyx SI technology* reduced DFU recurrence by up to 86% for people with diabetic peripheral neuropathy and a previous DFU. Neuropathy, which occurs in 70% of people with diabetes, is characterized by a lack of sensation and pain in the feet. Due to this lack of sensation, people with neuropathy often can't detect when tissue damage is occurring. It is the number one cause of lower-extremity amputations when left under-treated.

*Study was conducted with first generation SurroSense Rx® which has the same pressure algorithm as Orpyx SI Sensory Insoles

The development of the Orpyx SI Sensory Insole system was a true collaboration with our healthcare providers and patients, stated JR Locey, VP of Commercial Operations. For the first time, we are able to offer sensory feedback through a simple user interface to provide real-time data. Previously, this type of accuracy was only available in a research setting, but now it can be used in the real world to help prevent DFUs.

About Orpyx Medical Technologies Inc.

Orpyx® Medical Technologies Inc. empowers people with diabetes to maintain mobility. The company's core product line, the Orpyx SI Sensory Insoles with remote patient monitoring, helps manage and prevent diabetic foot ulcers and limb loss through advanced foot sensor technology and real-time analytics. Orpyx technology is also used by researchers to access clinical-grade plantar pressure data for health and human performance applications in the fields of sports medicine, therapeutic applications and footwear design.

You might also like

News
News

Orpyx secures $20M investment led by Perceptive Advisors

News

Siksika Health Services and Partners Expand Pilot Program to Enhance Foot Health and Prevent Diabetic Foot Ulcers Among Siksika Nation Members

News

Siksika Health Services, Orpyx, and GMAK Consulting Collaborate to Help Eliminate Foot Complications for Patients with Type 2 Diabetes through the PATHWAYS Indigenous Health Collaborations Program